The patient with BCR-ABL1 fusion and PRPS1 mutations and the other with T-ALL and NT5C2 mutation both had very short initial remission duration of 6 months (supplementary Table 3). The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.